Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $25.9K in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 12
- 13F valueReported value at the end of Q2 2026
- $498.3K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PCSA, Q2 2026
No superinvestor reported holding PCSA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Processa Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)4:20 PM ET | Jun 30 | 1 day | Guy WendyChief Administrative Officer | PPurchase | +2.44K | $1.93 | +$4.70K | +20.4%14.4K after | |
| Jul 1, 2026 (view filing)4:19 PM ET | Jun 30 | 1 day | Lin PatrickChief Business - Strategy Off | PPurchase | +2.11K | $1.93 | +$4.06K | +19.1%13.1K after | |
| Jul 1, 2026 (view filing)4:19 PM ET | Jul 1 | Same day | Ng George KChief Executive Officer | PPurchase | +3.06K | $1.93 | +$5.90K | +24.6%15.5K after | |
| Jul 1, 2026 (view filing)4:17 PM ET | Jun 30 | 1 day | Skibsted RussellChief Financial Officer | PPurchase | +3.28K | $1.93 | +$6.32K | +24.4%16.7K after | |
| Jul 1, 2026 (view filing)4:16 PM ET | Jun 30 | 1 day | Young DavidPres. Research & Development | PPurchase | +2.53K | $1.93 | +$4.88K | +13.2%21.7K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Young DavidPres. Research & Development | PPurchase | +2.07K | $2.22 | +$4.59K | +12.1%19.2K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Skibsted RussellChief Financial Officer | PPurchase | +2.65K | $2.22 | +$5.89K | +24.7%13.4K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Ng George KChief Executive Officer | PPurchase | +2.46K | $2.22 | +$5.47K | +24.7%12.4K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Lin PatrickChief Business - Strategy Off | PPurchase | +1.83K | $2.22 | +$4.06K | +20.0%11.0K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Guy WendyChief Administrative Officer | PPurchase | +2.12K | $2.22 | +$4.70K | +21.5%12.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Processa Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Connective Capital Management, LLC | 85,274 | $163.7K | 0.12% | +14,538+20.6% | Added |
| Stonepine Capital Management, LLC | 55,000 | $105.6K | 0.08% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 22,090 | $42.4K | 0.00% | −2,818−11.3% | Reduced |
| Citadel Advisors LLC | 21,306 | $40.9K | 0.00% | +21,306 | New |
| StoneX Group Inc. | 11,437 | $29.6K | 0.00% | +11,437 | New |
| XTX Topco Ltd | 13,292 | $25.5K | 0.00% | +13,292 | New |
| Jane Street Group, LLC | 13,264 | $25.5K | 0.00% | +13,264 | New |
| Vanguard Capital Management LLC | 12,729 | $24.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 10,857 | $20.8K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7,794 | $15.0K | 0.00% | +5,263+207.9% | Added |